This aligns with the high proportion of RAS/MAP kinase pathway activation in some pediatric tumor types (i.e., low‐grade gliomas, NF‐1‐related plexiform neurofibromas, LCH) and the growing body of evidence about safety and efficacy of these compounds,7, 21 but highlights the delays in obtaining regulatory approvals and reimbursement for drugs which are already considered as standard of care by many pediatric oncologists. This evidence concerns the gene NF1 and Langerhans cell histiocytosis.